Cargando…

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

INTRODUCTION: Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menzies-Gow, Andrew, Hoyte, Flavia L., Price, David B., Cohen, David, Barker, Peter, Kreindler, James, Jison, Maria, Brooks, Christopher L., Papeleu, Peggy, Katial, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056458/ https://www.ncbi.nlm.nih.gov/pubmed/35287231 http://dx.doi.org/10.1007/s12325-022-02098-1

Ejemplares similares

A Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
por: Menzies-Gow, Andrew, et al.
Publicado: (2022)

Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
por: Calzetta, Luigino, et al.
Publicado: (2022)

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Singh, Dave, et al.
Publicado: (2023)

Postbronchodilator lung function improvements with benralizumab for patients with severe asthma
por: Mathur, Sameer K., et al.
Publicado: (2020)

Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study
por: Menzies-Gow, Andrew, et al.
Publicado: (2022)

Vocal cord dysfunction: a review
por: Dunn, Neha M., et al.
Publicado: (2015)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2020)

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
por: Bleecker, Eugene R., et al.
Publicado: (2018)

PB2229: A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME
por: Ogbogu, Princess, et al.
Publicado: (2023)

Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis
por: Matsuno, Osamu, et al.
Publicado: (2022)

Holy Grail: the journey towards disease modification in asthma
por: Busse, William W., et al.
Publicado: (2022)

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma
por: FitzGerald, J Mark, et al.
Publicado: (2019)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
por: Caruso, Cristiano, et al.
Publicado: (2022)

Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Requena, Gema, et al.
Publicado: (2021)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
por: D'Amato, Maria, et al.
Publicado: (2022)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2021)

Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study
por: Numata, Takanori, et al.
Publicado: (2022)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Successful treatment of eosinophilic cystitis with benralizumab
por: Cooke, W Donald, et al.
Publicado: (2020)

Eosinophilic bronchiolitis successfully treated with benralizumab
por: Sugino, Keishi, et al.
Publicado: (2021)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia
por: Isomoto, Kohsuke, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
por: Nanzer, Alexandra M., et al.
Publicado: (2020)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Benralizumab for severe DRESS in two COVID-19 patients
por: Schmid-Grendelmeier, Peter, et al.
Publicado: (2021)

Real-life experience with benralizumab during 6 months
por: Padilla-Galo, A., et al.
Publicado: (2020)

Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab
por: Just, Jocelyne, et al.
Publicado: (2020)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Aminophylline/benralizumab: Lack of efficacy and eosinopenia: case report
Publicado: (2022)

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria
por: Magen, Eli, et al.
Publicado: (2022)

Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
por: BLOMBERG, Maria, et al.
Publicado: (2020)

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm(3): A Post Hoc Analysis from the ANANKE Study
por: Senna, Gianenrico, et al.
Publicado: (2022)

Benralizumab: a unique IL-5 inhibitor for severe asthma
por: Tan, Laren D, et al.
Publicado: (2016)

Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
por: George, Leena, et al.
Publicado: (2019)

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma
por: Yan, Li, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pblmjp45pc2qbfu4lat6lf1g56